DK0642530T3 - Dolastatinderivater - Google Patents

Dolastatinderivater

Info

Publication number
DK0642530T3
DK0642530T3 DK93909931T DK93909931T DK0642530T3 DK 0642530 T3 DK0642530 T3 DK 0642530T3 DK 93909931 T DK93909931 T DK 93909931T DK 93909931 T DK93909931 T DK 93909931T DK 0642530 T3 DK0642530 T3 DK 0642530T3
Authority
DK
Denmark
Prior art keywords
dolastatin
novel
derivates
formula
preparation
Prior art date
Application number
DK93909931T
Other languages
Danish (da)
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Application granted granted Critical
Publication of DK0642530T3 publication Critical patent/DK0642530T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK93909931T 1992-05-20 1993-05-10 Dolastatinderivater DK0642530T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88578892A 1992-05-20 1992-05-20
US98569692A 1992-11-25 1992-11-25
PCT/EP1993/001138 WO1993023424A1 (en) 1992-05-20 1993-05-10 Derivatives of dolastatin

Publications (1)

Publication Number Publication Date
DK0642530T3 true DK0642530T3 (da) 1998-10-26

Family

ID=27128772

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93909931T DK0642530T3 (da) 1992-05-20 1993-05-10 Dolastatinderivater

Country Status (21)

Country Link
EP (1) EP0642530B1 (fi)
JP (2) JP3523253B2 (fi)
KR (1) KR100286242B1 (fi)
CN (1) CN1065874C (fi)
AT (1) ATE169637T1 (fi)
AU (1) AU669710B2 (fi)
CA (1) CA2136339C (fi)
CZ (1) CZ292612B6 (fi)
DE (1) DE69320339T2 (fi)
DK (1) DK0642530T3 (fi)
ES (1) ES2118955T3 (fi)
FI (1) FI120692B (fi)
HU (2) HUT71398A (fi)
IL (1) IL105651A (fi)
MX (1) MX9302927A (fi)
NO (1) NO310465B1 (fi)
NZ (1) NZ252147A (fi)
RU (1) RU2116312C1 (fi)
SI (1) SI9300267A (fi)
UA (1) UA45304C2 (fi)
WO (1) WO1993023424A1 (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE4415998A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neue Tetrapeptide, ihre Herstellung Verwendung
DE4415997A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neuer peptidischer Wirkstoff und dessen Herstellung
DE19527574A1 (de) * 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung vona-(N,N-Dialkyl)-aminocaarbonsäureamiden
DE19527575A1 (de) * 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung von peptidischer Wirkstoffe
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
AU775090B2 (en) * 1995-12-15 2004-07-15 Abbvie Deutschland Gmbh & Co Kg Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686445B1 (en) 1997-09-24 2004-02-03 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
JP2001517604A (ja) * 1997-09-24 2001-10-09 アリゾナ ボード オブ リーゼンツ ドラスタチン１５から誘導された合成アンチネオプラスチック剤とその製造方法
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
DE60324964D1 (de) 2002-07-15 2009-01-08 Univ Princeton Iap-bindende verbindungen
TWI319707B (en) 2003-11-24 2010-01-21 Method of purifying pravastatin
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate

Also Published As

Publication number Publication date
HU211745A9 (en) 1995-12-28
IL105651A (en) 1998-07-15
MX9302927A (es) 1993-11-01
RU94046434A (ru) 1996-10-27
CA2136339A1 (en) 1993-11-25
DE69320339D1 (de) 1998-09-17
KR100286242B1 (ko) 2001-04-16
JP3523253B2 (ja) 2004-04-26
FI120692B (fi) 2010-01-29
FI945416A0 (fi) 1994-11-17
CN1085563A (zh) 1994-04-20
ATE169637T1 (de) 1998-08-15
EP0642530A1 (en) 1995-03-15
CA2136339C (en) 2008-02-05
RU2116312C1 (ru) 1998-07-27
ES2118955T3 (es) 1998-10-01
WO1993023424A1 (en) 1993-11-25
NO310465B1 (no) 2001-07-09
SI9300267A (sl) 1993-12-31
NO944419L (no) 1995-01-09
HUT71398A (en) 1995-11-28
FI945416A (fi) 1994-11-17
CZ292612B6 (cs) 2003-11-12
JP2004149538A (ja) 2004-05-27
UA45304C2 (uk) 2002-04-15
IL105651A0 (en) 1993-09-22
AU4066293A (en) 1993-12-13
EP0642530B1 (en) 1998-08-12
CN1065874C (zh) 2001-05-16
AU669710B2 (en) 1996-06-20
NZ252147A (en) 1996-10-28
CZ284394A3 (en) 1995-05-17
NO944419D0 (no) 1994-11-18
DE69320339T2 (de) 1998-12-17
JPH07506580A (ja) 1995-07-20

Similar Documents

Publication Publication Date Title
DK0642530T3 (da) Dolastatinderivater
MY124487A (en) Dolastatin derivatives, their preparation and use
DE69329425D1 (de) Dolastatin analog
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
FI930051A0 (fi) 4,13-dioxabicyklo(8.2.1)tridecenonderivat sam foerfarande och mellanprodukt foer deras framstaellning
DE69012619D1 (de) Bis(1-Hydrocarbyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-amin-derivate und stabilisierte Zusammensetzungen.
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
DK0570375T3 (da) Antikoagulatorisk virksomme peptider
MY114327A (en) Novel peptides, the preparation and use thereof
RU2001649C1 (ru) Тренажер
RU1809521C (ru) Генератор плазмы
RU1821413C (ru) Летательный аппарат
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
TH14157EX (th) เฟนิลเบนแซมีดสำหรับฆ่าราและกรรมวิธีสำหรับเตรียมสารนั้น
FR2671122B3 (fr) Plaque d'etancheite.
TR199801087T2 (xx) 4,10 �- diasetoksi-2alfa-Benzoiloksi- 5 �, 20 epoksi-1- hidroksi-9- okso-19- norsiklopropa(G) taks-11- en- 13alfa-il
IT8821384A0 (it) 5 pirimidincarbossamidi sostituite e composizioni farmaceutiche contenenti le stesse per il trattamento di leucemia.
TR27159A (tr) Sübstitüe edilmis 2 -fenil-5-(3-fenoksifelin (1,1,1-trifloropentanlari hazirlamaya mahsus yöntem ve aramaddeler.
DK467689D0 (da) X1200 h.w.w. 683480